New antibiotics still a decade away
To view this email as a web page, click here

Today's Rundown

Featured Story

Gilead's CD47 trials freed of FDA hold—for the most part

Gilead's CD47 cancer program is back on track—for the most part—after the FDA lifted clinical holds placed in January on five trials. But the agency is keeping two additional trials on ice, Gilead said Monday after market.

read more

Top Stories

AACR: Novartis hops on KRAS craze with early data, seeking to improve on undruggable target

Finding a way to drug KRAS-mutated cancers was a major leap forward for oncology, and we have Amgen to thank for getting the first therapy across the finish line. But Novartis, for one, sees room for improvement.

read more

New antibiotics still a decade away unless policymakers, investors step up, AMR Action Fund CEO warns

Despite the growing threat posed by drug-resistant bacteria, new antibiotics may not reach the market for another decade, according to the head of a $1 billion fund tasked with seeking out solutions.

read more

AACR: AbbVie's navitoclax goes after tough blood cancer, not yet reaching overall survival benchmark

Myelofibrosis is the cancer that keeps going and going—and AbbVie hopes new data from the phase 2 med navitoclax can make the case for stopping the rare and difficult-to-treat disease in its tracks.

read more

Carlyle's acquisition of Abingworth brings $2 billion to fuel life science investments

Carlyle Group is making its move into funding drug developers with mid-to-late-stage assets, absorbing transnational investment firm Abingworth. The two are also forming a new operating company to oversee, and hopefully better assist, the biopharmas they invest in.

read more

Eyes on the prize: Aurion Biotech raises $120M for 'global transformation in the cornea'

Aurion Biotech is setting its sights high with a mission to restore vision for millions of patients via regenerative therapies and a $120 million financing round to back the tech.

read more

Aeglea's search for signs of efficacy in phase 3 rare disease data impresses investors, sending stock up 30%

Aeglea BioTherapeutics’ bid to rehabilitate the battered reputation of its rare disease drug pegzilarginase has made early progress. Investors responded favorably to the presentation of additional phase 3 data, sending the stock up 21% in light of evidence the enzyme may act on clinical outcomes. 

read more

With $300M up for grabs, Engitix helps Takeda dig into extracellular matrix in search of IBD drugs

Takeda has tapped Engitix for a solution to an unmet need in inflammatory bowel disease (IBD). Having inked a $500 million deal to work with Engitix in liver diseases in 2020, Takeda has now put up a further $300 million to expand use of the extracellular matrix discovery platform to IBD.

read more

Charles River Labs says North American, EU plants will soon use 100% renewable energy

Charles River Laboratories says all its facilities in North America and Europe will run on “100% renewable” electricity starting next year.

read more

Liver enzyme might hold the secret to new obesity treatments

Scientists may have just made a breakthrough in treating the obesity epidemic, and the secret, it turns out, is in your liver. Researchers from The University of Texas Health Science Center at San Antonio found they could decrease appetite and increase fat shedding in obese mice after inhibiting a liver enzyme, with weight loss as the overall result. 

read more

The top 20 pharma companies by 2021 revenue

2021 was all about recovery from the COVID-19 pandemic. Several companies that quickly developed products to combat the coronavirus reaped huge profits, while others benefited simply from a return to more normalized business operations. Here's how the year shook out for the top 20 drugmakers by global revenues.

read more

Nationwide drug spending grew 7.7% in 2021, will increase another 4%-6% in 2022

Nonfederal hospitals saw an 8.4% increase in drug spending during 2021 while clinics shouldered a 7.7% gain, according to a recent report from the American Society of Health-System Pharmacists.

read more

Fitbit tails Apple Watch with FDA-cleared algorithm to passively check for afib

Fitbit's PPG technology is designed to work in the background throughout the day and night when a wearer is still or asleep.

read more

Wherefore Tavneos? ChemoCentryx and the Brand Institute explain how the #FierceMadness winner got its name

For more than three weeks, 68 drug names battled to become your FierceMadness champion, and in the end, that honor went to ChemoCentryx and its autoimmune disease drug Tavneos. Here's how the company and the Brand Institute came up with the name.

read more

Resources

eBook: 5 Rules to Enhance Wound Care & Dermatology Clinical Trials

Net Health, experts in wound care and dermatology clinical trials, have a new eBook: 5 Rules to Enhance Clinical Trials in 2022, find out how to recruit the right participants, connect patients and researchers with technology, manage costs and more.

Infographic: United Cargo: Providing Comprehensive Solutions For the Most Critical Shipments

The United Cargo team has made a commitment to pharmaceutical and medical partners that we are equipped to support their vaccine transportation needs safely and effectively across our expansive global and domestic network. The safety and security of these commodities is our priority, and we are proud to be a trusted partner in these efforts. Download infographic now.

Research: Get Access to AdisInsight A Year In Review

The journey of drug development in 2021 delivered to your inbox: top 10 AdisInsight drug profiles viewed, new drug profiles released, overview of drug launches, key deals, research trends in 2021 and much more (free of charge).

Whitepaper: Oncology Market Outlook: Key Trends to Watch

What’s in store for the oncology market in 2022 and beyond? This paper looks at 5 trends driving the market.

Whitepaper: Uncovering the hidden value of quality in chemical supply

Learn how to position quality as a central component within your raw material sourcing strategies for the chemicals used throughout your workflows. Download the free whitepaper from Thermo Fisher Scientific.

Whitepaper: Autologous CAR T-Cell Manufacturing: Semiautomatic, Closed, Modular Workflow

Learn how to navigate the top manufacturing challenges and achieve a seamless transition from discovery to clinical manufacturing across the CAR T-cell therapy workflow.

eBook: EMEA Regulatory Roadblocks around Decentralized Trials

Learn about ways to break down regulatory roadblocks and get closer to 100% clarity on regulatory positions to advance decentralized clinical trials in research.

Whitepaper: Lipid-Based Drug Delivery System to Bring Poorly Soluble Drugs to Market

How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market?

Whitepaper: Versatility of Softgel Technology - Encapsulation of a Volatile Compound

Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound.

Whitepaper: The Most Suitable Dosage Form Technologies for the Oral Delivery of Lipid-Based Formulations

What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations?

Webinar: The Faster Path From Pre-Filled Syringe to Auto-Injector

Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar.

Whitepaper: Formulation Strategies When Transitioning From Vial to PFS

Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.

Events